In this section
Clinical trials
- Participate in a clinical trial
- For medical professionals
- Active clinical trials for pediatric cancers
- CAR-20/19-T cells in pediatric and young adult patients with relapsed/refractory B Cell Acute Lymphoblastic Leukemia (CAR-20/19-T) phase 1 clinical trial
- Unrelated and partially matched related donor peripheral stem cell transplantation for patients with hematologic malignancies clinical trial
- Early stage research
Active clinical trials
Cancer Clinical Trials - COG-ARET2121
Protocol Summary
- Protocol No
- COG-ARET2121
- Principal Investigator
- Kerri Becktell
- Phase
- II
- Title
- Intravitreal Melphalan for Intraocular Retinoblastoma
- Associated Disease(s)
-
Retinoblastoma
- Description (Summary)
- In this study, we want to see if a drug called melphalan can be given along with standard chemotherapy. We want to find out if the combination of melphalan and standard chemotherapy is well tolerated and how well it works in children just diagnosed with RB. Melphalan is more commonly given later in therapy or if the cancer has come back after treatment. Study doctors hope that giving melphalan in addition to chemotherapy early in treatment will improve the ability to treat vitreous seeds. Melphalan is experimental because it has not been proven to work in a situation like yours. Although melphalan is experimental, it has been given into the vitreous (intravitreally) to a number of people with RB and has shown to be well-tolerated in children.
- Participating Institutions
- Childrens Hospital of Wisconsin
- ClinicalTrials.gov
Contact us
For more information about cancer and blood disorders clinical trials, email us or call
(414) 955-4727
Get a second opinion
It's important to know what your options are. We can provide expert opinions to verify or give more information about an initial diagnosis. Contact us today.
Why participate in clinical trials?
